Q10 therapy in patients with idiopathic Parkinson's disease.
A 3-month open-label trial was performed to evaluate the efficacy of 200 mg Q10 daily in 10 patients with Parkinson's disease. Motor performance was assessed with UPDRS and motor tests. There was no significant effect on the clinical ratings.
Strijks
E
E
Department of Neurology, University Hospital Nijmegen, The Netherlands.
Kremer
H P
HP
Horstink
M W
MW
D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D003067:Coenzymes; D006801:Humans; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects*; D012720:Severity of Illness Index; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000975:Antioxidants; D003067:Coenzymes; D018696:Neuroprotective Agents; D014451:Ubiquinone; C024989:coenzyme Q10